New Blood Test Measures Late-Stage Tau Tangles in Alzheimer’s

The assay, developed by researchers at Banner Sun Health Research Institute with Alamar Biosciences, detects a fragment of tau called eMTBR-tau243 that comes directly from the insoluble neurofibrillary tangles inside neurons.

Existing blood markers such as p-tau217 track soluble tau and amyloid well, but they plateau once tangles spread through the cortex — precisely when cognition declines fastest. In two autopsy cohorts totaling 521 brain donors, plasma eMTBR-tau concentrations jumped 50.5-fold and 25.2-fold between Braak stages I–II and stage VI, while p-tau217 rose only 4.6-fold and 3.2-fold over the same span.

— Nicholas Ashton, PhD, Banner Sun Health Research Institute

The test uses a high-sensitivity immunoassay requiring just 35 microliters of plasma, a fraction of the 1.5 milliliters needed for the mass-spectrometry method that first identified the marker. The BioFINDER-2 cohort showed a 0.93 correlation between the new immunoassay and mass spectrometry overall, rising to 0.96 among amyloid-positive participants. Both methods identified regional tau-PET positivity with area-under-the-curve values ranging from 0.96 to 0.99.

A panel approach could eventually let clinicians stage a patient’s biology more precisely and match them to anti-amyloid or anti-tau trials at the right moment.

Limitations are substantial. The study was cross-sectional, imaging cohorts were relatively small, and racial and ethnic diversity was limited. Many early-Braak values fell below the assay’s lower limit of quantification, so the test cannot yet detect the earliest tangle formation.

Larger prospective studies are needed to set clinical cutoffs, prove the marker predicts cognitive decline or treatment response, and validate performance across laboratories. Ashton said the low blood-volume requirement could enable remote collection and decentralized research, but those applications also need study.

The work was supported by multiple research grants and foundations. Bioventix supplied antibodies; Alamar Biosciences performed the immunoassay measurements. Ashton reported advisory, educational, and consulting relationships with several companies, including Alamar Biosciences. Marcal reported no disclosures.